Literature DB >> 23865556

Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats.

A Gottås1, E L Øiestad, F Boix, V Vindenes, Å Ripel, C H Thaulow, J Mørland.   

Abstract

BACKGROUND AND
PURPOSE: Heroin, with low affinity for μ-opioid receptors, has been considered to act as a prodrug. In order to study the pharmacokinetics of heroin and its active metabolites after i.v. administration, we gave a bolus injection of heroin to rats and measured the concentration of heroin and its metabolites in blood and brain extracellular fluid (ECF). EXPERIMENTAL APPROACH: After an i.v. bolus injection of heroin to freely moving Sprague-Dawley rats, the concentrations of heroin and metabolites in blood samples from the vena jugularis and in microdialysis samples from striatal brain ECF were measured by ultraperformance LC-MS/MS. KEY
RESULTS: Heroin levels decreased very fast, both in blood and brain ECF, and could not be detected after 18 and 10 min respectively. 6-Monoacetylmorphine (6-MAM) increased very rapidly, reaching its maximal concentrations after 2.0 and 4.3 min, respectively, and falling thereafter. Morphine increased very slowly, reaching its maximal levels, which were six times lower than the highest 6-MAM concentrations, after 12.6 and 21.3 min, with a very slow decline during the rest of the experiment and only surpassing 6-MAM levels at least 30 min after injection. CONCLUSIONS AND IMPLICATIONS: After an i.v. heroin injection, 6-MAM was the predominant opioid present shortly after injection and during the first 30 min, not only in the blood but also in rat brain ECF. 6-MAM might therefore mediate most of the effects observed shortly after heroin intake, and this finding questions the general assumption that morphine is the main and most important metabolite of heroin.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  CNS; acetylmorphine; distribution; heroin; metabolite kinetic; microdialysis; morphine; opioid; pharmacokinetic; prodrug

Mesh:

Substances:

Year:  2013        PMID: 23865556      PMCID: PMC3791993          DOI: 10.1111/bph.12305

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Opioids excite dopamine neurons by hyperpolarization of local interneurons.

Authors:  S W Johnson; R A North
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

2.  Cloning and expression of an isoform of the rat mu opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1.

Authors:  A Zimprich; T Simon; V Höllt
Journal:  FEBS Lett       Date:  1995-02-13       Impact factor: 4.124

3.  Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.

Authors:  A Avdeef; D A Barrett; P N Shaw; R D Knaggs; S S Davis
Journal:  J Med Chem       Date:  1996-10-25       Impact factor: 7.446

4.  Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception.

Authors:  G C Rossi; L Leventhal; Y X Pan; J Cole; W Su; R J Bodnar; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

Review 5.  Cellular and molecular mechanisms of drug dependence.

Authors:  G F Koob; F E Bloom
Journal:  Science       Date:  1988-11-04       Impact factor: 47.728

6.  Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection.

Authors:  T M Ludden; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1994-10

7.  Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1.

Authors:  A G Schuller; M A King; J Zhang; E Bolan; Y X Pan; D J Morgan; A Chang; M E Czick; E M Unterwald; G W Pasternak; J E Pintar
Journal:  Nat Neurosci       Date:  1999-02       Impact factor: 24.884

8.  Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms.

Authors:  Y X Pan; J Xu; E Bolan; C Abbadie; A Chang; A Zuckerman; G Rossi; G W Pasternak
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

9.  Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor.

Authors:  G C Rossi; Y X Pan; G P Brown; G W Pasternak
Journal:  FEBS Lett       Date:  1995-08-07       Impact factor: 4.124

10.  Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats.

Authors:  G C Rossi; K M Standifer; G W Pasternak
Journal:  Neurosci Lett       Date:  1995-09-29       Impact factor: 3.046

View more
  26 in total

Review 1.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 2.  Accessing analytes in biofluids for peripheral biochemical monitoring.

Authors:  Jason Heikenfeld; Andrew Jajack; Benjamin Feldman; Steve W Granger; Supriya Gaitonde; Gavi Begtrup; Benjamin A Katchman
Journal:  Nat Biotechnol       Date:  2019-02-25       Impact factor: 54.908

3.  The effect of economy type on heroin and saccharin essential value.

Authors:  Tommy Gunawan; Christopher S Tripoli; Alan Silberberg; David N Kearns
Journal:  Exp Clin Psychopharmacol       Date:  2019-03-21       Impact factor: 3.157

4.  Brain temperature effects of intravenous heroin: State dependency, environmental modulation, and the effects of dose.

Authors:  R Aaron Bola; Eugene A Kiyatkin
Journal:  Neuropharmacology       Date:  2017-07-27       Impact factor: 5.250

5.  Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Authors:  Kathryn L Schwienteck; Steven Blake; Paul T Bremer; Justin L Poklis; E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2019-08-24       Impact factor: 4.492

6.  Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats.

Authors:  Michael D Raleigh; Megan Laudenbach; Federico Baruffaldi; Samantha J Peterson; Michaela J Roslawski; Angela K Birnbaum; F Ivy Carroll; Scott P Runyon; Scott Winston; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-03-13       Impact factor: 4.030

7.  Using medical examiner case narratives to improve opioid overdose surveillance.

Authors:  Emily Hurstak; Christopher Rowe; Caitlin Turner; Emily Behar; Rachel Cabugao; Nikolas P Lemos; Catherine Burke; Phillip Coffin
Journal:  Int J Drug Policy       Date:  2018-01-30

8.  Post heroin dose tissue distribution of 6-monoacetylmorphine (6-MAM) with MALDI imaging.

Authors:  Belin G Teklezgi; Annapurna Pamreddy; Sooraj Baijnath; Nirmala D Gopal; Tricia Naicker; Hendrik G Kruger; Thavendran Govender
Journal:  J Mol Histol       Date:  2017-05-26       Impact factor: 2.611

9.  Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine.

Authors:  Kyungbo Kim; Jianzhuang Yao; Zhenyu Jin; Fang Zheng; Chang-Guo Zhan
Journal:  Chem Biol Interact       Date:  2018-08-04       Impact factor: 5.192

10.  Opposing mechanisms underlying differential changes in brain oxygen and temperature induced by intravenous morphine.

Authors:  Ernesto Solis; Anum Afzal; Eugene A Kiyatkin
Journal:  J Neurophysiol       Date:  2018-09-05       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.